Brandtree

Who owns Egoderm?

Egoderm is owned by Ego Pharmaceuticals (Australia).[1]

This ownership is reported in official statements but has not yet been matched to a regulatory filing.

Evidence: History - Ego Pharmaceuticals Australia. Last checked .

Key facts

Current owner
Ego Pharmaceuticals Pty Ltd reported
Owner HQ
🇦🇺 Australia
Origin
🇦🇺 Australia
Category
Personal care & beauty › Skin care › Dermocosmetics & clinical skin care
Last verified
· 1 sources

About Egoderm

Egoderm is an Ego Pharmaceuticals range of non-steroidal, cortisone-free products for dermatitis, eczema, rashes and dry, red skin. The company lists two versions: Egoderm Cream, with 1% ichthammol in a light emollient base, and Egoderm Ointment, which adds 15% zinc oxide in a thicker texture for scratched or broken skin and nappy rash.

Ownership timeline of Egoderm

  1. Current owner Ego Pharmaceuticals [1] reported

Where Egoderm sits in Ego Pharmaceuticals

Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.

Where Egoderm sits in Ego Pharmaceuticals Tree of 15 brands under Ego Pharmaceuticals. Ego Pharmaceuticals Egoderm Aqium Azclear DermAid EgoPsoryl TA Elucent and 9 more

Open the full Ego Pharmaceuticals ownership tree →

See the full Ego Pharmaceuticals brand portfolio (15) →

Other brands owned by Ego Pharmaceuticals

Ego Pharmaceuticals controls 15 brands on Brandtree, 15 of them in personal care & beauty.

Also in personal care & beauty

All Ego Pharmaceuticals brands →

Other brands in dermocosmetics & clinical skin care, and who owns them

Ego Pharmaceuticals has more brands in dermocosmetics & clinical skin care on Brandtree than any other owner: 9 of 41.

BrandOwnerOwner based in
Biretix Cantabria Labs 🇪🇸 Spain
CeraVe L'Oréal 🇫🇷 France
A-Derma Pierre Fabre 🇫🇷 France
Dermalogica Unilever 🇬🇧 United Kingdom
Minon Daiichi Sankyo Healthcare 🇯🇵 Japan
Alastin Galderma 🇨🇭 Switzerland
A-Solution Aekyung 🇰🇷 South Korea
Eucerin Beiersdorf 🇩🇪 Germany

Every brand in dermocosmetics & clinical skin care and its owner →

About the owner: Ego Pharmaceuticals

Ego Pharmaceuticals is a privately held company headquartered in Australia, founded in 1953. Brandtree records 15 brands under its control.

Ego Pharmaceuticals is an Australian-owned skincare and dermatology products company. Its own history page says it began in 1953, when the chemist Gerald Oppenheim and his wife Rae, a nurse, developed Pine Tar Bath Solution (now Pinetarsol) in the laundry of their Melbourne home. Their son Alan Oppenheim is Managing Director, and his wife Dr Jane Oppenheim is Chief Executive Officer. Its site lists manufacturing and support centres at Braeside and Dandenong South, Victoria, and regional offices in the Middle East and Asia. The brand list below is the one on its Our Brands page; no sun-care brand is on that list.

Ego Pharmaceuticals: full profile, brands and acquisition history →

🇦🇺 Egoderm and other Australian brands

Brandtree records a controlling owner for 203 brands that began in Australia. 59 of them (29%) are now controlled by a company headquartered in another country; Egoderm is not one of them.

All Australian brands and who owns them →

Frequently asked questions

Who is the parent company of Egoderm?

The parent company of Egoderm is Ego Pharmaceuticals, a privately held company headquartered in Australia.

Is Egoderm Australian?

Yes. Egoderm originated in Australia and its owner, Ego Pharmaceuticals, is also headquartered in Australia.

Is Egoderm still owned by Ego Pharmaceuticals?

Yes. As of 3 October 2026, Egoderm is still owned by Ego Pharmaceuticals. The ownership record was last checked against primary sources on that date.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] History - Ego Pharmaceuticals Australia — Ego Pharmaceuticals, Official document; retrieved 3 October 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.